Lineage Cell Therapeutics, Inc. - Common shares (LCTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / Common shares
Symbol
LCTX on NYSE
Shares outstanding
250,425,788
Price per share
$1.67
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
87,923,479
Total reported value
$148,571,752
% of total 13F portfolios
0%
Share change
-9,858,889
Value change
-$9,352,344
Number of holders
111
Price from insider filings
$1.67
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BROADWOOD PARTNERS, L.P. 23% -5.6% $97,763,723 57,848,357 0% NEAL C. BRADSHER 12 Nov 2025
Chernett Jorey 5% $13,848,454 11,445,003 Chernett Jorey 22 Sep 2025
BlackRock, Inc. 1% -80% $1,072,582 -$4,425,005 2,234,545 -80% BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 111 institutional investors reported holding 87,923,479 shares of Lineage Cell Therapeutics, Inc. - Common shares (LCTX). This represents 35% of the company’s total 250,425,788 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) together control 34% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BROADWOOD CAPITAL INC 20% 49,560,992 0% 5.1% $83,758,076
VANGUARD GROUP INC 3.6% 9,006,930 +6.2% 0% $15,221,712
RAFFLES ASSOCIATES LP 2.2% 5,387,788 -0.08% 8.5% $9,105,362
COMERICA BANK 1.8% 4,600,000 0% 0.03% $7,774,000
MILLENNIUM MANAGEMENT LLC 1.1% 2,680,003 +3.1% 0% $4,529,205
GEODE CAPITAL MANAGEMENT, LLC 0.97% 2,419,766 -0.49% 0% $4,091,534
BlackRock, Inc. 0.89% 2,230,756 -1.3% 0% $3,769,978
RENAISSANCE TECHNOLOGIES LLC 0.76% 1,905,633 -3.4% 0% $3,220,520
Dauntless Investment Group, LLC 0.64% 1,614,100 +34% 7.2% $2,727,829
MORGAN STANLEY 0.4% 1,006,451 +20% 0% $1,700,902
STATE STREET CORP 0.38% 955,622 +12% 0% $1,615,001
GSA CAPITAL PARTNERS LLP 0.27% 670,856 -25% 0.09% $1,134,000
RED CRANE WEALTH MANAGEMENT, LLC 0.2% 511,363 +3.1% 0.73% $864,203
NORTHERN TRUST CORP 0.18% 443,352 -13% 0% $749,264
Informed Momentum Co LLC 0.18% 442,221 0.09% $747,353
TWO SIGMA INVESTMENTS, LP 0.14% 354,347 +11% 0% $598,846
ROYAL BANK OF CANADA 0.12% 306,020 +18% 0% $517,000
BANK OF AMERICA CORP /DE/ 0.09% 233,436 +126% 0% $394,507
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.09% 221,000 +47% 0.01% $373,490
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.09% 218,274 +220% 0% $368,883
UBS Group AG 0.08% 208,080 -8.6% 0% $351,656
FMR LLC 0.08% 194,028 -0.44% 0% $327,908
CITADEL ADVISORS LLC 0.08% 193,968 +4.6% 0% $327,806
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.07% 185,000 -66% 0% $312,650
Quadrature Capital Ltd 0.07% 179,031 0% $304,353

Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 7,012,398 $11,711,232 +$11,461,304 $1.67 15
2025 Q3 87,923,479 $148,571,752 -$9,352,344 $1.69 111
2025 Q2 97,785,816 $88,366,897 -$8,826,208 $0.91 128
2025 Q1 109,349,495 $49,687,447 +$369,676 $0.45 126
2024 Q4 107,055,183 $53,800,251 +$3,893,520 $0.50 118
2024 Q3 94,568,251 $85,611,694 -$260,136 $0.91 113
2024 Q2 94,431,242 $94,175,358 +$447,436 $1.00 111
2024 Q1 93,427,423 $138,270,175 +$26,564,144 $1.48 113
2023 Q4 56,595 $61,689 $1.09 1
2023 Q3 75,504,077 $89,104,682 -$399,057 $1.18 102
2023 Q2 75,637,865 $106,647,723 +$8,582,432 $1.41 105
2023 Q1 69,793,059 $104,687,354 +$7,060,064 $1.50 114
2022 Q4 65,070,787 $76,138,155 +$641,868 $1.17 99
2022 Q3 64,492,417 $72,880,667 -$313,848 $1.13 86
2022 Q2 64,623,414 $102,117,821 -$10,316,534 $1.58 80
2022 Q1 72,813,378 $112,279,619 -$3,681,410 $1.54 97
2021 Q4 72,499,209 $177,620,026 -$3,159,689 $2.45 108
2021 Q3 73,322,476 $185,427,823 +$5,635,583 $2.52 103
2021 Q2 73,133,935 $208,480,180 +$35,608,571 $2.85 100
2021 Q1 60,312,187 $141,771,954 +$12,401,216 $2.35 89
2020 Q4 54,777,016 $96,404,191 +$3,090,452 $1.76 73
2020 Q3 53,553,927 $50,157,620 -$1,827,315 $0.94 63
2020 Q2 55,533,332 $48,315,841 -$6,846,381 $0.87 76
2020 Q1 63,762,517 $52,790,732 +$476,055 $0.83 78
2019 Q4 63,153,967 $56,200,085 -$1,197,402 $0.89 80
2019 Q3 64,396,609 $63,095,600 +$62,975,839 $0.98 78
2019 Q2 17,974 $20,000 +$20,000 $1.11 1